Latest Funding Agreements News

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Peak Rare Earths Limited has made significant strides in developing its Ngualla Rare Earth Project, completing an $8.5 million capital raise and progressing key negotiations with Shenghe Resources. Community initiatives and asset sales further underpin its growth strategy.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Finder Energy reports significant progress in its Kuda Tasi and Jahal oil fields development, including promising production simulations and active partner engagement for funding. The company also advances exploration efforts in the UK North Sea and Australia, maintaining a solid cash position.

Silver Mines Limited has secured $25 million in funding and released an updated Ore Reserve and Optimisation Study for its flagship Bowdens Silver Project, reinforcing its position as a leading silver developer in Australia.

Ioneer Ltd has closed a $996 million loan from the U.S. Department of Energy to accelerate its Rhyolite Ridge Lithium-Boron Project in Nevada, following key federal permitting milestones. Construction is targeted for 2025, promising to boost domestic critical mineral supply and create hundreds of jobs.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Volt Resources Limited has successfully repaid a AU$500,000 loan to RiverFort Global Opportunities, underscoring its financial discipline amid ongoing graphite project developments.

International Graphite advances its vision of a fully integrated graphite supply chain in Western Australia, securing significant government funding and delivering promising drilling and testwork results at its Springdale project.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

VIP Gloves Limited reports a sharp decline in quarterly sales receipts as it invests heavily in restarting manufacturing operations, while legal proceedings continue to loom.